drugset / Trial / NCT05315999

Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care

NCT05315999

Phase 2 Completed 30 enrolled Gerhild Becker
RandomizedParallel-groupTriple-blindTreatment

Summary

Palliative cancer patients with tumor pain often suffer from nausea and vomiting when starting pain therapy with opioids. The objective of the clinical pilot trial is to evaluate the efficacy and tolerability of palonosetron in the prophylactic treatment of opioid-induced nausea and vomiting.

Timeline

Start
2022-05-03
Primary completion
2024-12-18
Completion
2024-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Palonosetron Other / unclassified 500 ug Oral

Indications

No indication recorded.